ArticleMolecular cancer therapeutics2021
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.
Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05563766 (A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer), which is not on this map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Integration of FAERS database and network toxicology to investigate adverse drug events and potential toxicological mechanisms of triazole antifungal agents.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Repurposing Non-oncologic Drugs via Targeted Nanocarriers for Cancer Therapy: Mechanisms, Synergistic Combinations, and Clinical Translation.AAPS PharmSciTech · 2026Review
- Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights.RSC advances · 2026Review
- Itraconazole in the Treatment of Aberrantly Active Hedgehog and/or PI3K Recurrent Ovarian Cancer.Cancers · 2026Article
- PRSS23 functions downstream of ZEB1 to promote esophageal squamous cell carcinoma progression by driving M2 polarization of tumor associated macrophages.Molecular and cellular biochemistry · 2026Article
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- Itraconazole induced ferroptosis in acute myeloid leukemia cells through TP53INP1.Frontiers in molecular biosciences · 2026Article
- Exploratory high-throughput screening of repurposed drugs for canine lymphoid malignancies.BMC veterinary research · 2025Article
- Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen.Current issues in molecular biology · 2025Article
- METTL3/IGF2BP2 Promotes the Malignant Progression of Esophageal Cancer by Activating the PIK3CA/AKT Pathway.Thoracic cancer · 2025Article
- Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p-STAT3 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Itraconazole promotes melanoma cells apoptosis via inhibiting hedgehog signaling pathway-mediated autophagy.Frontiers in pharmacology · 2025Article
- Advances of aptamers in esophageal cancer diagnosis, treatment and drug delivery.Beilstein journal of nanotechnology · 2025Review
- Microbial infection and treatment strategies in cancer patients.Frontiers in microbiology · 2025Review
- In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71.Archives of virology · 2024Article
- Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy.Frontiers in oncology · 2024Review
- Review
- Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett's Esophagus.International journal of molecular sciences · 2023Review
- Repurposing antifungal drugs for cancer therapy.Journal of advanced research · 2023Review
- The roles and mechanisms of the lncRNA-miRNA axis in the progression of esophageal cancer: a narrative review.Journal of thoracic disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 1 country.
Wei ZhangEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Ankur S BhagwathEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Zeeshan RamzanEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Taylor A WilliamsEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Indhumathy SubramaniyanDepartment of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas.ORCID 0000-0002-1523-7022
Vindhya EdpugantiDepartment of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas.
Raja Reddy KallemDepartment of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas.
Kerry B DunbarEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Peiguo DingEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Ke GongDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas.
Samuel A GeurkinkDepartment of Internal Medicine, Methodist Dallas Medical Center, Dallas, Texas.ORCID 0000-0002-7714-3080
Muhammad S BegDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-3754-6627
James KimDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-2992-9222
Qiuyang ZhangDepartment of Medicine, Center for Esophageal Diseases, Baylor University Medical Center, Dallas, Texas.
Amyn A HabibHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Sung-Hee ChoiDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Ritu LapsiwalaDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Gayathri BhagwathDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Jonathan E DowellDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Shelby D MeltonEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Chunfa JieDepartment of Biochemistry and Nutrition, Des Moines University, Des Moines, Iowa.
William C PutnamDepartment of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas.ORCID 0000-0001-9338-4143
Thai H PhamEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas.
David H WangEsophageal Diseases Center, University of Texas Southwestern Medical Center, Dallas, Texas. David1.Wang@UTSouthwestern.edu.ORCID 0000-0002-5572-7595
VA North Texas Health Care System · USThe University of Texas Southwestern Medical Center · USTexas Tech University · USBaylor University Medical Center · USDes Moines University · USMethodist Dallas Medical Center · USUniversity of North Texas · US
Funding
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinomaR01CA258684 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KIM, JAMES · 2021 to 2025
$1.9MThe role of Nrf2 in mediating resistance to EGFR inhibition in glioblastomaR01CA244212 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HABIB, AMYN · 2020 to 2024
$1.9MTargeting vismodegib-resistant tumors using BH3 mimeticsR01CA196851 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KIM, JAMES · 2016 to 2020
$1.7MHedgehog signaling in the development of Barrett's esophagusR01DK097340 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, DAVID H · 2013 to 2017
$1.4MInteractions between inflammatory and oncogenic signaling pathways in GBMI01BX002559 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI HABIB, AMYN · 2014 to 2021
–Reflux-Induced Oxidative DNA Damage Repair Early in Barrett's CarcinogenesisI01CX001668 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI DUNBAR, KERRY BRANDT · 2018 to 2022
–BLRD VA I01 BX002559CSRD VA I01 CX001668NCI NIH HHS R01 CA196851NCI NIH HHS R01 CA244212NCI NIH HHS R01 CA258684NIDDK NIH HHS R01 DK097340
Abstract
Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of cancers. We sought to determine the effects of itraconazole on esophageal cancer and elucidate its mechanism of action. Itraconazole inhibited cell proliferation and induced G
Indexed as
AnimalsApoptosisCell CycleCell MovementCell ProliferationCytochrome P-450 CYP3A InhibitorsErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGene Expression Regulation, NeoplasticHumansItraconazoleMaximum Tolerated DoseMiceMice, Inbred BALB CAKT1 protein, humanCytochrome P-450 CYP3A InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesItraconazoleProto-Oncogene Proteins c-akt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05563766ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.